CryoPort (NASDAQ:CYRX) Announces Earnings Results

CryoPort (NASDAQ:CYRX) issued its quarterly earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05, Zacks reports. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. CryoPort updated its FY 2025 guidance to EPS.

CryoPort Price Performance

CYRX traded up $0.18 during midday trading on Tuesday, hitting $9.22. 1,314,180 shares of the company traded hands, compared to its average volume of 569,853. The company has a current ratio of 16.24, a quick ratio of 15.47 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $461.62 million, a price-to-earnings ratio of 6.93 and a beta of 1.61. CryoPort has a 52-week low of $4.58 and a 52-week high of $11.44. The business has a 50 day simple moving average of $9.54 and a two-hundred day simple moving average of $7.90.

Insider Buying and Selling at CryoPort

In other CryoPort news, Director Robert J. Hariri sold 25,000 shares of the stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $9.71, for a total transaction of $242,750.00. Following the transaction, the director directly owned 51,275 shares of the company’s stock, valued at $497,880.25. This trade represents a 32.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Robert Stefanovich sold 9,300 shares of the stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $8.67, for a total transaction of $80,631.00. Following the transaction, the chief financial officer directly owned 207,213 shares in the company, valued at approximately $1,796,536.71. The trade was a 4.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 39,300 shares of company stock worth $366,381. Insiders own 10.00% of the company’s stock.

Hedge Funds Weigh In On CryoPort

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CYRX. Bank of America Corp DE raised its position in shares of CryoPort by 20.2% in the second quarter. Bank of America Corp DE now owns 397,421 shares of the company’s stock valued at $2,965,000 after buying an additional 66,677 shares during the last quarter. AQR Capital Management LLC raised its position in shares of CryoPort by 285.5% in the first quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock valued at $1,597,000 after buying an additional 194,482 shares during the last quarter. Rhumbline Advisers raised its position in shares of CryoPort by 17.6% in the second quarter. Rhumbline Advisers now owns 92,098 shares of the company’s stock valued at $687,000 after buying an additional 13,778 shares during the last quarter. American Century Companies Inc. raised its position in shares of CryoPort by 24.4% in the second quarter. American Century Companies Inc. now owns 88,876 shares of the company’s stock valued at $663,000 after buying an additional 17,459 shares during the last quarter. Finally, Federated Hermes Inc. raised its position in shares of CryoPort by 233.2% in the second quarter. Federated Hermes Inc. now owns 84,937 shares of the company’s stock valued at $634,000 after buying an additional 59,446 shares during the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on CYRX. Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a research note on Wednesday, October 8th. Leerink Partnrs raised shares of CryoPort from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 6th. BTIG Research upped their price objective on shares of CryoPort from $10.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, September 18th. KeyCorp raised shares of CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 price objective on the stock in a report on Wednesday, August 6th. Finally, Stephens began coverage on shares of CryoPort in a report on Tuesday, July 22nd. They issued an “overweight” rating and a $13.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $12.56.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.